MY162708A - Use of selected lactic acid bacteria for reducing infantile colic - Google Patents

Use of selected lactic acid bacteria for reducing infantile colic

Info

Publication number
MY162708A
MY162708A MYPI20071631A MYPI20071631A MY162708A MY 162708 A MY162708 A MY 162708A MY PI20071631 A MYPI20071631 A MY PI20071631A MY PI20071631 A MYPI20071631 A MY PI20071631A MY 162708 A MY162708 A MY 162708A
Authority
MY
Malaysia
Prior art keywords
lactic acid
acid bacteria
selected lactic
infantile colic
strains
Prior art date
Application number
MYPI20071631A
Other languages
English (en)
Inventor
Eamonn Connolly
Bo Möllstam
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38790468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY162708(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of MY162708A publication Critical patent/MY162708A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MYPI20071631A 2006-06-05 2007-05-30 Use of selected lactic acid bacteria for reducing infantile colic MY162708A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/446,628 US7374924B2 (en) 2006-06-05 2006-06-05 Use of selected lactic acid bacteria for reducing infantile colic

Publications (1)

Publication Number Publication Date
MY162708A true MY162708A (en) 2017-07-14

Family

ID=38790468

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20071631A MY162708A (en) 2006-06-05 2007-05-30 Use of selected lactic acid bacteria for reducing infantile colic

Country Status (20)

Country Link
US (3) US7374924B2 (https=)
EP (1) EP2040722B1 (https=)
JP (3) JP4520531B2 (https=)
KR (2) KR101030661B1 (https=)
CN (2) CN101374533B (https=)
AU (2) AU2007200434B2 (https=)
BR (1) BRPI0710944B8 (https=)
CA (1) CA2650546C (https=)
DK (1) DK2040722T3 (https=)
GE (1) GEP20125480B (https=)
HU (1) HUE026416T2 (https=)
IL (1) IL194779A0 (https=)
MX (1) MX2008014869A (https=)
MY (1) MY162708A (https=)
NZ (2) NZ572359A (https=)
RU (1) RU2435844C2 (https=)
SI (1) SI2040722T1 (https=)
UA (1) UA93911C2 (https=)
WO (1) WO2007142596A1 (https=)
ZA (1) ZA200809531B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
SG188887A1 (en) * 2008-03-14 2013-04-30 Nestec Sa Synbiotic mixture
CA2742476A1 (en) * 2008-11-03 2010-06-03 Nestec S.A. A nutritional composition comprising probiotics and improving sleep patterns
AU2014221272B2 (en) * 2008-11-03 2016-01-21 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
US20110104327A1 (en) * 2009-04-23 2011-05-05 Bacterfield International S.A. Probiotic pet food
WO2011012655A1 (en) 2009-07-31 2011-02-03 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
NL2004101C2 (en) * 2010-01-15 2011-07-18 Friesland Brands Bv Ruminant il-10 and use in modulating immune response.
IT1401460B1 (it) * 2010-06-11 2013-07-26 Probiotical Spa "ceppi di batteri probiotici produttori di vitamina b12"
KR101706100B1 (ko) * 2011-12-15 2017-02-15 삼성전자주식회사 성형한계선도 획득용 시험장치
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
US10265351B2 (en) * 2013-08-09 2019-04-23 Ab-Biotics, S.A. Probiotic for infantile colic
US20160334391A1 (en) 2014-01-23 2016-11-17 Biogaia Ab Selection of Agents Modulating Gastrointestinal Pain
EP3212208B1 (en) * 2014-10-29 2021-03-03 Biogaia AB Use of l. reuteri for prevention or treatment of microbiota dysbiosis in early life
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
JP6529835B2 (ja) * 2015-06-23 2019-06-12 株式会社フィス 樹状細胞活性化剤
CN105219683B (zh) * 2015-11-04 2018-03-13 广东省农业科学院动物科学研究所 一株具有益生特征的罗伊氏乳杆菌菌株及其应用
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
CN106497840B (zh) * 2016-11-07 2019-06-21 江南大学 一种定向分离免疫调节性肠道乳杆菌的方法
EP3827102A1 (en) * 2018-07-24 2021-06-02 Biogaia AB Therapeutic methods using bacterial strains which are capable of increasing adenosine levels
IL305597B2 (en) * 2018-07-24 2024-08-01 Biogaia Ab Selection and use of melatonin-supporting bacteria to reduce infantile tinea
JP7556881B2 (ja) * 2019-04-17 2024-09-26 バイオガイア エイビー プロバイオティック細菌の治療用マイクロベシクル
WO2022203379A1 (ko) * 2021-03-26 2022-09-29 서울대학교산학협력단 유산균의 생리활성 효능 증진용 조성물
CN117925484B (zh) * 2024-03-19 2024-07-09 山东中科嘉亿生物工程有限公司 一株改善睡眠呼吸暂停的罗伊氏粘液乳杆菌jylb-101及其产品和应用
WO2025206977A1 (ru) * 2024-03-29 2025-10-02 Александр Владимирович Синица Штамм бактерий lactobacillus reuteri, подавляющий активность helicobacter pylori

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518696A (en) 1983-01-11 1985-05-21 Chr. Hansen's Laboratory, Inc. Stabilized liquid bacterial suspension for oral administration to animals
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5534253A (en) 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
ES2199305T3 (es) 1995-12-21 2004-02-16 Biogaia Ab Uso de lactobacillus reuteri para inhibir criptosporidiosis en mamiferos.
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US5800813A (en) 1996-11-12 1998-09-01 Biogaia Biologics Ab Treatment of cryptosporidium infections
KR19990024297A (ko) 1997-08-07 1999-04-06 오종석 인체 구강내 치태형성을 억제하는 신규한 유산균
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
EP1034788A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
EP1344458A1 (en) * 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
MXPA05003743A (es) * 2002-10-18 2005-06-17 Biogaia Ab Metodo para mejorar la funcion inmunologica en mamiferos utilizando cepas de lactobacillus reuteri.
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20040185032A1 (en) 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
ES2326481T3 (es) * 2003-06-23 2009-10-13 Nestec S.A. Formula para recien nacidos o formula de continuacion.
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
US20060251634A1 (en) * 2005-05-06 2006-11-09 Ho-Jin Kang Method of improving immune function in mammals using lactobacillus strains with certain lipids
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic

Also Published As

Publication number Publication date
HK1125840A1 (en) 2009-08-21
HUE026416T2 (en) 2016-07-28
US20120121564A1 (en) 2012-05-17
US9057112B2 (en) 2015-06-16
AU2010202976B2 (en) 2012-12-20
NZ572359A (en) 2011-12-22
RU2008147883A (ru) 2010-07-20
CN102488717A (zh) 2012-06-13
EP2040722A1 (en) 2009-04-01
GEP20125480B (en) 2012-04-25
BRPI0710944B8 (pt) 2021-05-25
US7374924B2 (en) 2008-05-20
NZ596788A (en) 2013-03-28
BRPI0710944A2 (pt) 2017-04-18
US9340840B2 (en) 2016-05-17
ZA200809531B (en) 2010-03-31
WO2007142596A1 (en) 2007-12-13
BRPI0710944B1 (pt) 2020-12-29
KR101030661B1 (ko) 2011-04-20
CN101374533A (zh) 2009-02-25
EP2040722A4 (en) 2010-06-02
MX2008014869A (es) 2008-12-05
JP2009539371A (ja) 2009-11-19
JP5865283B2 (ja) 2016-02-17
US20080131414A1 (en) 2008-06-05
DK2040722T3 (en) 2016-02-01
JP2010202654A (ja) 2010-09-16
RU2435844C2 (ru) 2011-12-10
EP2040722B1 (en) 2015-11-11
CA2650546C (en) 2011-08-02
KR20090015903A (ko) 2009-02-12
JP4520531B2 (ja) 2010-08-04
AU2010202976A1 (en) 2010-08-05
KR20100080565A (ko) 2010-07-08
AU2007200434B2 (en) 2010-09-02
SI2040722T1 (sl) 2016-02-29
CN101374533B (zh) 2012-02-01
CA2650546A1 (en) 2007-12-13
JP2013173749A (ja) 2013-09-05
CN102488717B (zh) 2018-03-27
IL194779A0 (en) 2009-08-03
US20070280913A1 (en) 2007-12-06
UA93911C2 (ru) 2011-03-25
AU2007200434A1 (en) 2007-12-20
KR101308865B1 (ko) 2013-09-17

Similar Documents

Publication Publication Date Title
MY162708A (en) Use of selected lactic acid bacteria for reducing infantile colic
UA101316C2 (ru) Применение отобранных молочнокислых бактерий для профилактики и лечения атеросклероза
MY173382A (en) Infant feeding formulas comprising probiotic micro-organisms
SG196782A1 (en) Compositions and methods for the increased production of isoprene and other products with 6 - phosphogluconolactonase (pgl)
MX338201B (es) Bacterias acidolacticas de postacidificion baja.
UA107711C2 (en) Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
CA2710814C (en) Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation
MX2010008137A (es) Bacterias no patogenas y/o atenuadas capaces de inducir apoptosis en macrofagos, proceso de fabricacion y su usos.
EP3831951A3 (en) Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
PH12013502105A1 (en) Nutritional products comprising human milk oligosaccharides and methods for manufacture thereof
MX2011007930A (es) Conjugados de insulina cristalina.
EP4413994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
NZ602544A (en) Crystalline forms of a macrolide, and uses therefor
MY198870A (en) Producing edible residues from ethanol production
MX2012007970A (es) Proceso para la preparacion de una biomasa que comprende plantaricina y usos de la misma en el campo medico.
TW200510449A (en) Acylated nonadepsipeptides
PH12013500929A1 (en) Non-replicating probiotic bacteria and prevention or treatment of infections to reduce absence from school or daycare
MX2010002978A (es) Formulacion nutritiva con alto contenido energetico.
NZ595217A (en) Composition for producing a fungicide and a biological bactericide
PL2224820T3 (pl) Produkty żywnościowe
PH12020551922A1 (en) Selection and use of melatonin supporting bacteria to reduce infantile colic
IL194353A0 (en) Lysobactin amides
TW200621799A (en) Acylated nonadepsipeptides II
PL1724340T3 (pl) Szczepy bakterii kwasu mlekowego wrażliwe na antybiotyk
MY158393A (en) Tumour cytotoxic agent and methods thereof